1.Spaide RF. Choroidal Neovascularization. Retina. 2017;37(4):609–10.
2.Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137(3):486–95.
3.Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, et al. EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study. Retina. 2018;38(8):1464–77.
4.Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137(3):496–503.
5.Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103(8):1241–4.
6.Yin H, Fang X, Ma J, Chen M, Yang Y, Guo S, et al. Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment. Sci Rep. 2016;6:31880.
7.Carneiro AM, Silva RM, Veludo MJ, Barbosa A, Ruiz-Moreno JM, Falcao MS, et al. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica. 2011;225(2):81–8.
8.Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Am J Ophthalmol. 2012;153(2):300–6.e1.
9.Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.
10.Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–98.
11.Skelly A, Bezlyak V, Liew G, Kap E, Sagkriotis A. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision (Basel). 2019;3(3).
12.Zhou P, Yang L, Jin X. Ranibizumab versus bevacizumab for the treatment of idiopathic choroidal neovascularization: 2-Year results. Eur J Ophthalmol. 2016;26(3):262–7.
13.Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–67.
14.Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531–8.
15.Grover S, Murthy RK, Brar VS, Chalam KV. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51(5):2644–7.
16.Fan X, Gao N, Li J, Lei J, Kang Q. Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization. Mol Cell Biochem. 2018;441(1–2):173–9.
17.Sii F, Lee LR. Retinopathy associated with photodynamic therapy for treatment of idiopathic choroidal neovascularization. Clin Exp Ophthalmol. 2006;34(2):184–6.
18.Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina. 2017;37(10):1847–58.
19.Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77–88.
20.Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1):e000398.
21.Zhao M, Bai Y, Xie W, Shi X, Li F, Yang F, et al. Interleukin–1beta Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV). PLoS One. 2015;10(5):e0125150.
22.Sudhalkar A, Yogi R, Chhablani J. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study. Retina. 2015;35(7):1368–74.
23.Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.
24.Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol. 2018;18(1):130.
25.Inoue M, Kadonosono K, Watanabe Y, Sato S, Kobayashi S, Yamane S, et al. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Retina. 2010;30(5):733–8.
26.Nishimura T, Machida S. Correlation between macular structure and function in patients with age-related macular degeneration treated with intravitreal ranibizumab: 12-month-results. Jpn J Ophthalmol. 2019;63(1):90–9.
27.Rufai SR, Almuhtaseb H, Paul RM, Stuart BL, Kendrick T, Lee H, et al. A systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond). 2017;31(9):1337–44.
28.Guo S, Yin H, Zheng M, Tang Y, Lu B, Chen X, et al. Cytokine profiling reveals increased serum inflammatory cytokines in idiopathic choroidal neovascularization. BMC Ophthalmol. 2019;19(1):94.
29.Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Long-Term Outcome and Recurrence of Idiopathic Choroidal Neovascularization Treated with Intravitreal Bevacizumab. J Ocul Pharmacol Ther. 2016;32(7):431–6.
30.Tran TH, Querques G, Forzy G, Souied EH. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2011;42(6):498–508.
31.Wakazono T, Yamashiro K, Oishi A, Ooto S, Tamura H, Akagi-Kurashige Y, et al. RECURRENCE OF CHOROIDAL NEOVASCULARIZATION LESION ACTIVITY AFTER AFLIBERCEPT TREATMENT FOR AGE-RELATED MACULAR DEGENERATION. Retina. 2017;37(11):2062–8.
32.Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123(8):1751–61.